Samuel Lederman

2.4k total citations · 2 hit papers
18 papers, 1.3k citations indexed

About

Samuel Lederman is a scholar working on Endocrinology, Diabetes and Metabolism, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Samuel Lederman has authored 18 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Genetics and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Samuel Lederman's work include Estrogen and related hormone effects (7 papers), Menopause: Health Impacts and Treatments (6 papers) and Cardiac electrophysiology and arrhythmias (5 papers). Samuel Lederman is often cited by papers focused on Estrogen and related hormone effects (7 papers), Menopause: Health Impacts and Treatments (6 papers) and Cardiac electrophysiology and arrhythmias (5 papers). Samuel Lederman collaborates with scholars based in United States, United Kingdom and Spain. Samuel Lederman's co-authors include Alfred H. Moffett, Pirow Bekker, Alan Kivitz, Mark Peterson, Michael R. McClung, Paul D. Miller, Grattan C. Woodson, Michael A. Bolognese, Donna Holloway and Charles H. Chesnut and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Samuel Lederman

17 papers receiving 1.3k citations

Hit Papers

Denosumab in Postmenopausal Women with Low Bone Mineral D... 2006 2026 2012 2019 2006 2023 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Denosumab in Postmenopausal Women with Low Bone Mineral Density
    2006 886 citations Michael R. McClung, E. Michael Lewiecki et al. New England Journal of Medicine profile →
  2. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study
    2023 122 citations Samuel Lederman, Antonio Cano et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Samuel Lederman United States 11 681 561 546 297 288 18 1.3k
L. K. Heilbrun United States 11 264 0.4× 194 0.3× 70 0.1× 46 0.2× 67 0.2× 18 861
Nadia Verbruggen United States 16 820 1.2× 729 1.3× 828 1.5× 168 0.6× 35 0.1× 31 1.4k
S. Radominski Brazil 16 121 0.2× 111 0.2× 141 0.3× 47 0.2× 88 0.3× 54 970
Thomas A Ratko United States 16 143 0.2× 172 0.3× 27 0.0× 175 0.6× 51 0.2× 32 813
Richard D. Baerg United States 6 90 0.1× 111 0.2× 66 0.1× 406 1.4× 100 0.3× 9 1.2k
Renate Thalhammer Austria 14 405 0.6× 181 0.3× 19 0.0× 63 0.2× 40 0.1× 35 1.0k
S Caponnetto Italy 19 485 0.7× 307 0.5× 22 0.0× 27 0.1× 109 0.4× 85 1.2k
H Enright United States 21 200 0.3× 313 0.6× 75 0.1× 53 0.2× 22 0.1× 29 1.4k
A N Békássy Sweden 17 305 0.4× 239 0.4× 19 0.0× 122 0.4× 26 0.1× 31 1.4k
T Cooke United Kingdom 15 333 0.5× 171 0.3× 8 0.0× 190 0.6× 57 0.2× 35 894

Countries citing papers authored by Samuel Lederman

Since Specialization
Citations

This map shows the geographic impact of Samuel Lederman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel Lederman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel Lederman more than expected).

Fields of papers citing papers by Samuel Lederman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel Lederman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel Lederman. The network helps show where Samuel Lederman may publish in the future.

Co-authorship network of co-authors of Samuel Lederman

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel Lederman. A scholar is included among the top collaborators of Samuel Lederman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel Lederman. Samuel Lederman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Lederman, Samuel, et al.. (2025). Sustained Efficacy of Oteseconazole in Women with Recurrent Vulvovaginal Candidiasis. Journal of Women s Health. 35(3). 334–339.
2.
Neal-Perry, Genevieve, Antonio Cano, Samuel Lederman, et al.. (2023). Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause. Obstetrics and Gynecology. 141(4). 737–747. 59 indexed citations
3.
Lederman, Samuel, Antonio Cano, Nanette Santoro, et al.. (2023). Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. The Lancet. 401(10382). 1091–1102. 122 indexed citations breakdown →
4.
Gregory, David A., et al.. (2023). A real-world comparison of the clinical and economic utility of OVA1 and CA125 in assessing ovarian tumor malignancy risk. Journal of Comparative Effectiveness Research. 12(6). e230025–e230025. 8 indexed citations
5.
Lederman, Samuel, Marla Shapiro, Petra Stute, et al.. (2022). Phase 3 Study of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause [A132]. Obstetrics and Gynecology. 139(1). 39S–39S. 5 indexed citations
6.
Schwebke, Jane R., Ryan Sobel, Janet Gersten, et al.. (2021). Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303). Clinical Infectious Diseases. 74(11). 1979–1985. 62 indexed citations
7.
Fraser, Graeme L., Samuel Lederman, Arthur Waldbaum, et al.. (2020). A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause The Journal of The North American Menopause Society. 27(4). 382–392. 75 indexed citations
8.
Santoro, Nanette, Arthur Waldbaum, Samuel Lederman, et al.. (2020). Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause The Journal of The North American Menopause Society. 27(12). 1350–1356. 44 indexed citations
9.
Fraser, Graeme L., Samuel Lederman, Arthur Waldbaum, et al.. (2019). OR33-6 The Neurokinin 3 Receptor Antagonist, Fezolinetant, Is Effective in Treatment of Menopausal Vasomotor Symptoms: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study. Journal of the Endocrine Society. 3(Supplement_1). 3 indexed citations
10.
11.
McClung, Michael R., E. Michael Lewiecki, Stanley Cohen, et al.. (2006). Denosumab in Postmenopausal Women With Low Bone Mineral Density. Obstetrical & Gynecological Survey. 61(6). 384–386. 16 indexed citations
12.
McClung, Michael R., E. Michael Lewiecki, Stanley Cohen, et al.. (2006). Denosumab in Postmenopausal Women with Low Bone Mineral Density. New England Journal of Medicine. 354(8). 821–831. 886 indexed citations breakdown →
13.
Lederman, Samuel, et al.. (1989). Effects of Flecainide on Occlusion and Reperfusion Arrhythmias in Dogs. Journal of Cardiovascular Pharmacology. 13(4). 541–546. 15 indexed citations
14.
Lederman, Samuel, et al.. (1989). Effects of Flecainide on Occlusion and Reperfusion Arrhythmias in Dogs. Journal of Cardiovascular Pharmacology. 13(4). 541–546. 17 indexed citations
15.
Lederman, Samuel, Thomas L. Wenger, Frank E. Harrell, & Harold C. Strauss. (1987). Effects of different paced heart rates on canine coronary occlusion and reperfusion arrhythmias. American Heart Journal. 113(6). 1365–1369. 10 indexed citations
16.
17.
Rk, Freeman, et al.. (1984). Nonreactive contraction stress test: clinical significance.. PubMed. 64(3). 337–42. 2 indexed citations
18.
Wenger, Thomas L., Frank E. Harrell, Kathleen K. Brown, Samuel Lederman, & Harold C. Strauss. (1984). Ventricular fibrillation following canine coronary artery reperfusion: different outcomes with pentobarbital and α-chloralose. Canadian Journal of Physiology and Pharmacology. 62(2). 224–228. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. K. Heilbrun Breakdown of academic impact, for papers by Nadia Verbruggen Breakdown of academic impact, for papers by S. Radominski Breakdown of academic impact, for papers by Thomas A Ratko Breakdown of academic impact, for papers by Richard D. Baerg Breakdown of academic impact, for papers by Renate Thalhammer Breakdown of academic impact, for papers by S Caponnetto Breakdown of academic impact, for papers by H Enright Breakdown of academic impact, for papers by A N Békássy Breakdown of academic impact, for papers by T Cooke
Rankless by CCL
2026